Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

16 Jun 2020

Abstract excerpt

PURPOSE Homologous DNA repair–deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DNA repair–proficient OCs. However, clinical evidence is lacking. The study aimed to evaluate the associations between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32923884
DOI: 10.1200/po.20.00069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerPMID 32923884Read ↗

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Semantic proximity Read ↗

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.Semantic proximity Read ↗

The mutation and clonality profile of genomically unstable high grade serous ovarian cancer is established early in tumor development and conserved throughout therapy resistanceSemantic proximity Read ↗

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancersSemantic proximity Read ↗

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read ↗

Identification of three subtypes of ovarian cancer and construction of prognostic models based on immune-related genes.Semantic proximity Read ↗

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.Semantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and TreatmentSemantic proximity Read ↗

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.Semantic proximity Read ↗

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.Semantic proximity Read ↗

Distinct genomic profiles are associated with treatment response and survival in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.